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tiveness ratios for stage 5 without and with CPEs were Rp7,870,936.19 and
Rp7,137,874.93, respectively. ICERs was Rp1,486,786.41 for CKD stage 4 and
Rp234,898.33 for CKD stage 5. CONCLUSIONS: Treatment of CKD stage 4 and 5 with
CPE was more effective and cost-effective compared to those without CPE. The
ICERs indicated that extra costs were required to increase life saved in both stages.
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COMPARISON OF QUALITY OF LIFE BETWEEN HEMODIALYSIS AND
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OBJECTIVES: To compare health-related quality-of-life (HRQoL) in patients on hemo-
dialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) in a tertiary hos-
pital in China.METHODS: From September 2004 to January 2005, adult patients on
HD or CAPD for at least 6 months were recruited with clinical and HRQoL data
collected by medical records review and patient survey. Patients’ HRQoL was as-
sessed by KDQOL-SF including SF-36 as the generic and 11 disease-specific do-
mains with higher scores indicating better HRQoL. RESULTS: Eighty-six patients
[50 on CAPD and 36 on standard HD (3x4-hour weekly)] were included for the
analysis, with 55% male and a mean age of 57.715.6 years. No differences were
found in age, sex, education, payment method, income, originating disease, hae-
moglobin level, and dialysis time between HD and CAPD. CAPD patients had a
higher score (SD) compared to HD patients for Effects of Kidney Disease (EKD:
55.1(15.8) vs. 40.8(10.2), p .0001), Symptom/Problem List (SPL: 67.8(12.6) vs.
59.5(7.7), p 0.0005), Quality of Social Interaction (QSI: 65.0(13.9) vs. 58.1(9.1), p
0.006) and Patient Satisfaction (PS: 70.0(12.1) vs. 60.7(13.3), p0.001). CAPD group vs.
HDalsohadhigher scoresonBodyPain (BP: 60.2(14.2) vs. 45.4(18.1), p 0.0003), General
Health (GH: 33.6 (15.1) vs. 26.7(11.7), p0.03), Role-Emotional (RE: 61.4(25.5) vs.
41.7(33.2), p0.002) and Mental Health (MH: 67.3(14.0) vs. 55.3(19.4), p 0.002) from
SF-36 assessment. Controlling for key factors/covariates, CAPD patients still showed
better scores comparing toHDpatients inEKD,SPL, PS, BP,REandMH.Olderage, lower
haemoglobin level and originating disease of hypertension were shown to be associ-
ated with lower scores of certain dimensions compared to their counterparts,
respectively. CONCLUSIONS: CAPD patients showed better HRQoL in EKD, SPL,
PS, BP, RE and MH than HD patients in this study population. The findings may
help understand HRQoL burden and influential factors among dialysis patients.
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WHAT IS THE EVIDENCE ON USING SELECTED TYPES OF SUTURES FOR
ABDOMINAL SURGERY – NOVEL APPROACH TO CREATE DYNAMIC TOOL FOR
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Skarzynska-Duk J1, Jaros P1, Metz L2, Tsao J2, Plisko R1, Wladysiuk M1, Rys P1
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OBJECTIVES: To obtain availability and assess the quality of existing evidence on
effectiveness of poliglecaprone, polydioxanone and polyglactin-910 when used in
different abdominal layers suturing.METHODS: Studies were identified by means
of systematic search in MEDLINE, EMBASE and CENTRAL databases. Supplemen-
tary search for ongoing trials was also conducted. All studies published since 2000
and evaluating at least one of the selected interventions, with exception to case
reports and cross sectional studies, were regarded as appropriate. Data selection
was performed independently by two reviewers. Each study was characterized in
detail according to predefined categories. Quality of those trials was assessed using
Jadad or NOS scale depending on the type of the study. All information were sub-
sequently exploited to create Dynamic Literature Catalogue – a novel toll for quick
and efficient data reviewing. RESULTS: Among 119 positions qualified for full text
analysis 40 publications met our inclusion criteria. Majority of those studies (n 
30) were designed as RCTs, eight were non-randomized comparative studies, one
was conducted in a single arm scheme. Sixteen trials had their center location
situated in Asia region. Twenty-six studies were considered as large trials includ-
ing  100 patients. Target population comprised mainly adult patients. Main re-
ported outcomes were wound infection or other complications, healing and cos-
mesis effects and patients satisfaction. All data extracted from publication were
included in the Dynamic Literature Catalogue. To make reviewing of all selected
information more efficient, we categorized them into several domains distin-
guished in accordance with PICO scheme. Appropriate filters allowing for quick
data selection and analyzing were used in each domain. CONCLUSIONS: There is
numerous of available evidence on using poliglecaprone, polydioxanone and
polyglactin-910 in different abdominal layers suturing. We showed that reviewing
and analyzing this data can be simplified and adjusted to different area of interest
when Dynamic Literature Catalogue is used.
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OBJECTIVES: Although the WHO fracture risk assessment tool (FRAXTM) has been
developed, its algorithm is unpublished and not necessarily available for economic
evaluations. The purpose of this studywas to develop a health economicmodel for
assessing the cost-effectiveness of osteoporosis treatment in postmenopausal
womenwith rheumatoid arthritis, who have received combination therapy includ-
ing corticosteroids in Japan.METHODS:We constructed risk equations for age and
bone mineral density (BMD)-specific fracture applying a series of methods pro-
posed by De Laet CE et al (1997) to epidemiological data unique to Japanese. A state
transition model with six health states (no fracture, post-vertebral fracture, post-
hip fracture, post-vertebral and hip fracture, bedridden, and death) was developed
to predict a ten year probability of hip fracture and the ten year probability of a
major osteoporoetic fracture. Model validity was verified by comparison of the
predicted fracture probabilities by different combination of age (55 to 65 years) and
BMD (T-score -1.5 to -2.5) between the developed model and FRAX. RESULTS: Indi-
vidual simulation for 1,000womenaged 55, 60 and 65 years resulted in the expected
life years of 31.3 to 32.3, 27.1 to 27.9 and 22.9 to 23.6, respectively, about the same as
in national life table in Japan. The predicted probability of hip fracture in women
with T-score -1.5, -2.0 and -2.5were ranged to 0.8 to 1.4%, 1.4 to 2.5% and 2.9 to 5.1%,
respectively, and consistent with those of FRAX as follows: 0.8 to 1.9%, 1.5 to 3.1%
and 2.8 to 5.2%, respectively. As expected, our model had the tendency to slightly
underestimate the probability of a major fracture because the model did not con-
sider an occurrence of humerus fracture and wrist fracture. CONCLUSIONS: The
model newly developed was validated and helpful for determining the cost-effec-
tive treatment thresholds for corticosteroid-induced osteoporosis in postmeno-
pausal women with rheumatoid arthritis.
RESEARCH ON METHODS - Cost Methods
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STANDARD COST LIST FOR ECONOMIC EVALUATION IN THAILAND
Riewpaiboon A
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OBJECTIVES: To develop standard unit costs of medical services provided by dif-
ferent health facilities, cost of patients coming for treatments, and reference values
used in the economic evaluation.METHODS: The project was conducted as a num-
ber of sub-projects. Analysis of unit cost of medical services was conducted in 5
hospitals employing the relative value unit method. Cost of health center services
was calculated in 19 health centers employing standard costing andmicro-costing
methods. Cost of pharmaceutical services was analysed in 11 hospitals. Logistics
cost of vaccines under the national vaccination program covered the supply chain
from the central supplier to provincial health offices. Cost of patients coming to
have treatments was collected by interviewing 900 patients from 6 health centers,
3 district hospitals and 3 provincial/regional hospitals. Reference values were ob-
tained from documentary research. RESULTS: The results were published in a
book, and can be accessed via the Health Intervention and Technology Assessment
(HITAP) website (http://db.hitap.net/). They are composed of 3091 items of hospital
medical services in two categories of hospitals: district and provincial/regional
hospitals. Services of hospital pharmacy departments, and health services pro-
vided by health centers, include 9 and 68 items, respectively. Logistics cost of
vaccines is presented as cost per dose of the vaccine supplied. Cost of patients is
composed of distance, time, transportation cost and meal cost. Reference values
are useful years of capital assets (i.e. buildings, vehicles, furniture and equipment),
minimumwage, and gross domestic product per capita. CONCLUSIONS: This stan-
dard cost menu and reference values should make economic evaluations faster
and more convenient. This is the first standard cost menu to be developed for
Thailand. Some limitations exist, whichwill be improved upon in the next revision.
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OBJECTIVES: Some insist that productivity loss should not be included in costs
when using quality-adjusted life year (QALY) because QALY also reflects the influ-
ence of work loss and thus results in “double counting.” “Double counting” of QALY
and productivity loss is a controversial issue, particularly given the lack of empir-
ical data addressing the influence of income reduction on utility scores.METHODS:
In this study, we performed a web-based, large-sample survey to address the issue
of double counting. To determine the influence of income reduction on utility
scores, we obtained utility scores of eight health states with three instruction
types: a) no instruction; b) instructed to consider income reduction; and c) in-
structed not to consider income reduction (compensated). Respondents were ran-
domly sampled from the on-line panel adjusted by age and sex. Theywere asked to
evaluate one of 24 patterns by both standard gamble (SG) and time trade-off (TTO)
methods. RESULTS: A total of 6551 respondents completed the questionnaire. Re-
spondent demographics were similar to the Japanese general population. First,
despite the lack of instruction on income reduction, many respondents spontane-
ously assumed lost income. The proportion tended to be higher when considering
more severe health states. Second, the degree of assumed income reduction was
related to utility scores. For a 10% income reduction, respondents assumed a 0.02 to
0.04 decrease in utility score (both SG and TTO methods). Third, utility scores did
not change significantly, even when the decrease in income was compensated. In
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our view, the effect of income does not only reflect money they lost.
CONCLUSIONS: An assumed income reduction clearly influenced utility scores,
however compensation for lost income fail to improve utility scores. Our results
suggest that income does not significantly influence utility scores and that the
impact of double counting is negligible.
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SYSTEMATIC REVIEW OF COST-UTILITY ANALYSES IN ASIA
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OBJECTIVES: To review published cost-utility analyses (CUA) targeted towards
populations in Asia.METHODS:We examined data from the Tufts Medical Center
Cost-Effectiveness Analysis Registry (www.cearegisty.org), which contains de-
tailed information on more than 2,900 English-language CUAs in peer-reviewed
journals. We focused on articles pertaining to Asian countries, summarized study
features for articles published from 2000-2010, and compared those with CUAs in
all other countries. RESULTS: Of 2,367 CUAs published during 2000-2010, 87 (3.7%)
pertained to Asian countries: Japan (n34), Taiwan (n18), China (n9), Thailand
(n7), Hong Kong (n5), Singapore (n5), South Korea (n5), India (n4), and
Bangladesh (n1). The CUAs contained 243 standardized incremental cost-effec-
tiveness ratios (ICERs, expressed as $US2010 per QALY) and 357 utility weights. The
most common type of intervention was pharmaceuticals (52.9%), followed by
screening (21.8%), diagnostics (11.5%), and surgery (11.5%). 79 CUAs (90.8%) men-
tioned a cost-effectiveness threshold; of these, 60 said “good value for money”
reflected a threshold below $50,000/QALY. The median reported ICER was $11,000/
QALY, vs. $21,000/QALY for non-Asian studies. 75.7% of the reported ICERs were
either dominant (less expensive and more effective) or below $50,000/QALY, com-
pared to 63.9% in non-Asian CUAs (p0.001). 13.6% of ICERs were either dominated
(more expensive and less effective) or greater than $100,000/QALY, compared to
22.4% in non-Asian CUAs (p0.001). CUAs targeted towards Asian populations gen-
erally adhered to good methodological practices, though the average quality score
wasmodestly lower than the overall mean (4.08 vs. 4.43, p0.001) and significantly
more studies did not report funding sources (40.2% vs. 22.2%, p0.001), compared
with non-Asian CUAs. CONCLUSIONS: The number of CUAs in Asia has grown
steadily with over half focused on pharmaceuticals. Compared to CUAs in all other
countries, significantly more studies in Asia suggest efficient health interventions.
These CUAs generally follow good methodological practices though reporting of
funding sources could improve.
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OBJECTIVES: Indirect cost is an important component in cost-of-illness assess-
ment. This study explored the factors involved in the variation of reported indirect
cost and investigated the feasibility of transferring indirect costs across settings.
METHODS: A systematic literature review was conducted to identify studies esti-
mating indirect costs for four selected chronic diseases, namely, asthma (AS), dia-
betes (DI), rheumatoid arthritis (RA), and schizophrenia (SC). Multiple linear regres-
sion was run to identify the factors that potentially explain the variation of
reported indirect costs. Parametric (fixed and random-effect model) and non-para-
metric (bootstrappingmethod)meta-analyses were applied to local gross domestic
product (GDP) per capita adjusted indirect costs for each disease. RESULTS: Sys-
tematic literature review identified 77 articles that reported indirect costs of AS
(18), DI (20), RA (25), and SC (14) for literature synthesis. Substantial inter- and
intra-disease variations among the indirect cost studies were observed, regarding
the geographic distribution, methodology and magnitude of cost estimation. Re-
gression analysis showed disease categories and local GDP per capita significantly
(P0.001) contributed to the variance of indirect cost. The range of intra-disease
variation in indirect cost was subsatntially reduced after adjusting by and express-
ing as of local GDP/capita. GDP adjusted indirect cost in terms of percentage of local
GDP/capita of AS was the lowest and that of SC was the highest. Bootstrapping
estimation was relatively conservative with slightly larger confidence intervals
than the parametric method with themean (95%CI) of 2.12% (1.4089, 2.9332) on AS,
10.65% (7.215, 14.7438) on DI, 21.98% (17.4360, 27.0631) on RA, and 79.19% (52.4243,
117.833) on SC. CONCLUSIONS: It would be convenient and feasible to construct a
universal reference range of indirect cost for a specific disease based on existing
data and presented as a percentage of local GDP to assist local decision making in
jurisdictions where indirect cost data are not available.
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OBJECTIVES: Singapore has a modified universal health care system in which sub-
sidy rates are pegged to household incomes and other socioeconomic attributes.
Out-of-pocket charges vary considerably for each service and level of subsidy.
Hence, costing issue needs to be carefully considered in cost utility study in the
context of Singapore, depending on the perspective from which the analyses are
performed. This research was to explore the costing consideration for different
possible scenarios through an illustrative cost utility analysis. METHODS: Using
the incremental cost and QALY gained data presented in a published cost utility
analysis of a treatment for breast cancer in the context of Singapore, hypothetical
scenarioswere assumed for different levels of subsidy (50%, 75% and 100%) covered
by the public health care provider that a patient might receive at a government
restructure hospital. Assuming the QALY gained remains the same, incremental
cost per QALY gained (ICER) was computed for each scenario from the perspective
of the public health care provider. RESULTS: For a fully subsidy scenario (100%), the
total incremental costwas S$62,770. In the case of subsidy rates at 50%and 75%, the
incremental total costs were S$31,385 and S$47,077, respectively. For the same
expected gained of 1.70 QALYs, the resulting ICERs were S$18,462, S$27,692 and
S$36,924 for scenarios of 50%, 75% and 100% subsidy rates, respectively.
CONCLUSIONS: Due to the possible different subsidy rates for most of the costing
items in a cost utility analysis, careful considerationwith explicit cost computation
from a clearly defined perspective is recommended. Aweighted total cost based on
the distribution of possible subsidy levels and relevant sensitivity analyses should
be considered in a pharmacoeconomic study from the perspective of the public
health care provider of Singapore.
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OBJECTIVES: Both Korea and Australia have stringent pharmaco-economic (PE)
guidelines outlining the data requirements for cost effectiveness analysis (CEA).
The requirements for regulatory approval in both countries are clear and mainly
rely on multinational clinical trials with the addition of relative small bridging
studies in Korea. It seems, however, to be different for reimbursement submission
where CEAs are presented.The purpose of this study is to uncover the data require-
ments for CEA from an industry perspective.METHODS: Firstly a literature search
was performed to find any relevant publications. Moreover website of decision
maker’s were searched for past reimbursement decisions. Finally a qualitative
comparison was made of the PE guidelines for Korea and Australia. RESULTS: The
literature search revealed very little published literature on CEAs as part of drug
reimbursement submissions inKorea andAustralia. Decisionmakers in both coun-
tries publish reimbursement decisions on their respective website. However the
information disclosed rarely reveals what input data was used for CEAs. The PE
guidelines for the respective countries showed remarkable similar data require-
ments. The main difference is surrounding local resource data. In Korea this usu-
ally retrieved through information gathering exercises like cost and utilisation
studies. It is quite different in Australia where most information is available either
through a government website or as IMS data. CONCLUSIONS: Both Korea and
Australia has specific requirements for CEAs however the local data needed for
each country differs significantly. Acquiring cost and utilisation data in Australia
seems straight forward in most cases, whereas the situation is different in Korea.
Not only does it have an impact on time to market for new innovative pharmaceu-
ticals but it also increases the uncertainty surrounding the result of the CEA mak-
ing it more difficult for decision makers to make a decision.
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OVERVIEW OF THE PROLABELS DATABASE SIX YEARS AFTER ITS
IMPLEMENTATION
Perrier LL, Caron M, Murison A
MAPI Research Trust, Lyon, France
OBJECTIVES:The PROLabels database (www.mapi-prolabels.org) is a unique online
tool collecting information on the medical and biological products for which the
Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
have granted a Patient-Reported Outcome (PRO) labeling claim. The purpose of this
abstract is to present an overview of the database six years after its implementa-
tion in April 2006. METHODS: To create the database, data were retrieved on the
EMA website, from the European Public Assessment Reports for all the drugs ap-
proved through a centralized procedure since 1995. Evidence of a PRO endpointwas
pulled for each product from the Summary of Product Characteristics and, when
necessary, additional information was gathered from the scientific discussions.
From the FDAwebsite, datawere collected from the approved labels and additional
information was retrieved in the Medical Reviews. The database now contains all
drugs approved or revised by the FDA since 1995, including Biological Approvals
(BLAs). For the purpose of this review, all approvals between 1995 and 2011 were
reviewed individually for each agency. RESULTS: As of December 31, 2011, the
database contains 486 records of which 342 products were approved by the FDA
(22.6% of all FDA approvals). Therewere 144 productswith a PRO claim approved by
the EMA (24.2% of all EMA approvals). Nervous system diseases is the therapeutic
area for which the highest number of products is approved with a PRO claim
(n153), followed by the immune system diseases (n105). Signs and symptoms
are the most frequently measured PROs while health-related quality-of-life repre-
sents only 16.9% of all drugs approved with a PRO claim. CONCLUSIONS: The
PROLabels database provides easy access to information regarding PRO claims in
approved labels for both FDA and EMA in one location and information about PRO
claims trends in the USA and Europe.
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EVIDENCE FOR VALIDITY OF A NATIONAL PATIENT-REPORTED SURVEY IN
JAPAN: THE JAPAN NATIONAL HEALTH AND WELLNESS SURVEY
Dibonaventura MD1, Fukuda T2, Stankus A3
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